GlycoMark®
Also known as: GlycoMark®, 1-5 Anhydroglucitol
Use
GlycoMark® testing provides an estimate of the patient's postmeal glucose over a one- to two-week period, making it ideal for intermediate term monitoring of glycemic control in diabetic patients. GlycoMark® testing can also help monitor the effectiveness of therapeutics targeting postprandial glucose (PPG)1,2 and is a useful adjunct to routine A1c testing, because it responds more rapidly and sensitively to hyperglycemia than A1c.1,2
Special Instructions
Not provided.
Limitations
Individuals using INVOKANA® may demonstrate low levels of 1,5-AG, as it is lowered by the diabetes drug which prevents reabsorption in the kidneys. Persistent urinary glucose levels or oxyhyperglycemia after gastrectomy may cause low 1,5-AG values. Low values have also been observed in conditions like pregnancy, terminal renal failure, advanced cirrhosis, and more. Some medications and treatments can alter 1,5-AG values as described in the document. Abnormal values may also occur in cases with abnormal glomerular filtration rates. Always interpret GlycoMark® results alongside clinical findings and other diagnostics.
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 53835-5
- 53835-5
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.75 mL
Container
Red-top tube
Collection Instructions
Separate serum or plasma from cells within one hour of collection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 14 days |